The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03983525 |
Recruitment Status :
Completed
First Posted : June 12, 2019
Last Update Posted : July 23, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Objective: To evaluate the effects of goji berry intake for three months on macular pigment ocular density (MPOD) between 45 and 65 years old.
Specific Aims:
Determine if goji berry intake for 90 days, 5 times per week, will:
- result in favorable changes in macular pigment optical density (MPOD), as measured using heterochromatic flicker photometry (HFP), in adults aged from 45 to 65 years old.
- impact the carotenoid distribution in the skin.
- will change the fermentation capacity of the gut microbiota.
The investigators hypothesize that the intake of 28 grams of goji berry for 90 days, 5 days per week will significantly increase MPOD after three months, compared to baseline values. In contrast, the investigators hypothesize that a dietary supplement of lutein and zeaxanthin will not alter MPOD.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Macular Pigment Optical Density | Dietary Supplement: Goji berry Dietary Supplement: Lutein + zeaxanthin supplementation | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 31 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Randomized paralleled arm clinical trial |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function |
Actual Study Start Date : | June 10, 2019 |
Actual Primary Completion Date : | May 28, 2020 |
Actual Study Completion Date : | June 15, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Goji berry
The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0 SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with either a 45-day supply of goji berries and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
|
Dietary Supplement: Goji berry
Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take 28 grams of goji berry once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24. |
Active Comparator: Lutein + zeaxanthin supplementation
The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0. SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with L/Z supplements which contains 6 mg of lutein and 4 mg of zeaxanthin and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
|
Dietary Supplement: Lutein + zeaxanthin supplementation
Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take one capsule of lutein + zeaxanthin supplementation once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24. |
- Macular pigment ocular density (MPOD) [ Time Frame: 90 days ]MPOD measurement - MPOD will be assessed by the psychophysical method of HFP technology (Macular Metrics, Providence, RI). Participants will watch a 20 minutes long video of a description of HFP. After adapting to the dark for seven minutes, participants will be asked to rest their head on a chin rest and look at a blue background field for three minutes. Prior to each test, the light intensity from each wavelength will be calibrated with a photodiode. The flicker frequency is selected for each subject based on preliminary tests of flicker sensitivity. The observer's task is to eliminate or minimize the flicker by turning a dial that changes the intensity of the 460-nm light. They will be asked to do this when looking directly at the flickering light and also when looking at a fixation point so that the stimulus can be presented in the periphery.
- Skin carotenoids concentration [ Time Frame: 90 days ]Skin carotenoid measurement - the carotenoid content in the skin will be measured through a finger-scanning device using reflection spectroscopy (this process does not capture fingerprints) called the Veggie Meter (VM). This noninvasive method of measuring skin carotenoid levels has been validated to reflect plasma carotenoid concentrations.
- Gut fermentation measured as the hydrogen content in the breath [ Time Frame: 90 days ]Breath Hydrogen measurement - the participant will be asked to do one short exhalation (about 2-3 seconds) into a collection tube. Their breath sample will be analyzed for hydrogen and methane that are produced by fermentation of carbohydrates (including fiber) in the digestive tract.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion:
Male and female:45-65 years Willing and able to comply with the study protocols Normal macular condition verified by optometry office Stable on prescription medication use, for at least the past 6 months, as approved by the study physician
Exclusion:
Dislike of or allergy to goji berry Self-reported diabetes, renal or liver disease, heart disease, which includes cardiovascular events and stroke, cancer, malabsorption problems, substance abuse or eye diseases
Smoking:
- Current smokers
- Those that have smoked within the past year
- Former smokers with greater than a 20 pack-year history of smoking within the past 20 years Indications of substance or alcohol abuse Current or planned use of blood thinner (eg. Coumadin, Warfarin) at any time during study
Currently taking zeaxanthin or lutein supplements Use of multi-vitamin and mineral supplements other than a general formula that provides up to 100% of the Daily Value Not willing to stop dietary supplement use at least one month prior to study enrollment Currently taking drugs for management of lipids, glucose or blood pressure statin drugs A current enrollee in a clinical research study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03983525
United States, California | |
Regal Human Nutrition Research Center | |
Davis, California, United States, 95616 |
Responsible Party: | University of California, Davis |
ClinicalTrials.gov Identifier: | NCT03983525 |
Other Study ID Numbers: |
1220178 |
First Posted: | June 12, 2019 Key Record Dates |
Last Update Posted: | July 23, 2020 |
Last Verified: | July 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |